Drug Combination Details
| General Information of the Combination (ID: C55738) | |||||
|---|---|---|---|---|---|
| Name | Daunorubicin NP Info | + | Oxaliplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | TOP2A | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Composite micelles showed reduced systematic toxicity and greater synergistic effect than combination of small molecules of hydrophilic platinum drug Oxa(II) and hydrophobic drug DRB both in vitro and in vivo. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy. J Control Release. 2012 Nov 10;163(3):304-14. | |||
